Design, synthesis and in vitro/in vivo evaluation of orally bioavailable prodrugs of a catechol-O-methyltransferase inhibitor.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Bioorganic & Medicinal Chemistry Letters

• Publication date

  2010-04-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bmcl.2010.02.057PMID 20231095
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Olmesartan Medoxomil

  2012cited by this paper
• Enalapril

  2012cited by this paper
• Tenofovir Disoproxil Fumarate

  2012cited by this paper
• Adefovir Dipivoxil

  2012cited by this paper
• Levodopa/carbidopa/entacapone in Parkinson’s disease

  2009cited by this paper
• Water-soluble prodrugs of the human immunodeficiency virus protease inhibitors lopinavir and ritonavir.

  2009cited by this paper
• Levodopa for the treatment of Parkinson's disease.

  2008cited by this paper
• Prodrugs: design and clinical applications

  2008cited by this paper
• Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting.

  2008cited by this paper
• Pharmacokinetics, Metabolism, and Excretion of the Intestinal Peptide Transporter 1 (SLC15A1)-Targeted Prodrug (1S,2S,5R,6S)-2-[(2′S)-(2-Amino)propionyl]aminobicyclo[3.1.0.]hexen-2,6-dicarboxylic acid (LY544344) in Rats and Dogs: Assessment of First-Pass Bioactivation and Dose Linearity

  2007cited by this paper
• Enzymes involved in the bioconversion of ester-based prodrugs.

  2006cited by this paper
• Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection.

  2005cited by this paper
• Microplate screening assay to identify inhibitors of human catechol-O-methyltransferase.

  2004cited by this paper
• Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist.

  2003cited by this paper
• Synthesis and conformational analysis of a coumarinic acid-based cyclic prodrug of an opioid peptide with modified sensitivity to esterase-catalyzed bioconversion.

  2002cited by this paper
• Different toxicological profile of two COMT inhibitors in vivo: the role of uncoupling effects

  2002cited by this paper
• Effects of entacapone and tolcapone on mitochondrial membrane potential.

  2002cited by this paper
• Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man

  2001cited by this paper
• Induction and repair of formaldehyde-induced DNA-protein crosslinks in repair-deficient human cell lines.

  2000cited by this paper
• Selective plasma hydrolysis of glucocorticoid gamma-lactones and cyclic carbonates by the enzyme paraoxonase: an ideal plasma inactivation mechanism.

  2000cited by this paper
• Adefovir dipivoxil. Commentaries

  1999cited by this paper
• Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent.

  1998cited by this paper
• Neuropathology of Parkinson's Disease

  1996cited by this paper
• Synthesis of Iodoalkylacylates and Their Use in the preparation of S-Alkyl Phosphorothiolates

  1995cited by this paper
• Expression of enzymatically active rat liver and human placental catechol-O-methyltransferase in Escherichia coli; purification and partial characterization of the enzyme.

  1992cited by this paper
• Comparative pharmacokinetic study between lenampicillin, bacampicillin and amoxycillin.

  1989cited by this paper
• A comparative pharmacokinetic study between lenampicillin, bacampicillin and amoxycillin.

  1989cited by this paper
• Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

  1986cited by this paper
• Studies on prodrugs. II. Preparation and characterization of (5-substituted 2-Oxo-1,3-dioxolen-4-yl)methyl esters of ampicillin.

  1984cited by this paper
• Studies on prodrugs. II. Preparation and characterization of (5-substituted 2-oxo-1,3-dioxolen-4-yl)methyl esters of ampicillin.

  1984cited by this paper
• Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man

  1979cited by this paper

• New self-organised benzo[b]thiophene-based materials for GHz applications

  2024cites this paper
• Medicinal chemistry-based perspectives on thiophene and its derivatives: exploring structural insights to discover plausible druggable leads.

  2024cites this paper
• Preclinical Evaluation of an Imidazole-Linked Heterocycle for Alzheimer’s Disease

  2023cites this paper
• Discovery and characterization of flavonoids in vine tea as catechol-O-methyltransferase inhibitors.

  2021cites this paper
• Prodrug approach for posterior eye drug delivery: synthesis of novel ganciclovir prodrugs and in vitro screening with cassette dosing.

  2020cites this paper
• Neurological and psychiatric management using COMT inhibitors: A review.

  2019cites this paper
• An overview of benzo[b]thiophene-based medicinal chemistry.

  2017cites this paper
• Design of Lipophilic Prodrugs to Improve Drug Delivery and Efficacy.

  2016cites this paper
• Medicinal chemistry of catechol O-methyltransferase (COMT) inhibitors and their therapeutic utility.

  2014cites this paper
• Inhibitors of catechol-O-methyltransferase in the treatment of neurological disorders.

  2013cites this paper
• Inhibitors of Catechol-O-Methyltransferase.

  2012cites this paper
• Microbial β-glycosylation of entacapone by Cunninghamella echinulata ATCC 9245.

  2012cites this paper
• Designing prodrugs for the treatment of Parkinson's disease

  2012cites this paper
• Five-Membered Ring Systems: Thiophenes and Se/Te Derivatives

  2011cites this paper
• The rationality for using prodrug approach in drug discovery programs for new xenobiotics: opportunities and challenges

  2011cites this paper
• Biochemistry and pharmacology of catechol-O-methyltransferase inhibitors.

  2010cites this paper
• Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.

  2010cites this paper